NCT01959867View on ClinicalTrials.gov

SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Breast Cancer
Interventions
DEVICE

SurgiMend® PRS

Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).

OTHER

No Intervention

Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).

Sponsors
All Listed Sponsors
lead

Integra LifeSciences Corporation

INDUSTRY

NCT01959867 - SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy | Biotech Hunter | Biotech Hunter